Stanley Fahn

Stanley Fahn's AcademicInfluence.com Rankings

Stanley Fahn

Medical

#462

Historical Rank

Neurology

#35

Historical Rank

medical Degrees

Download Badge

Medical

Stanley Fahn's Degrees

Doctorate Medicine Columbia University

Why Is Stanley Fahn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stanley Fahn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 (1998) (3363)
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale (1987) (3306)
Unified Parkinson's Disease Rating Scale (1987) (2728)
Recent Developments in Parkinson's Disease (1986) (2310)
Levodopa and the progression of Parkinson's disease. (2004) (1676)
Phenomenology and classification of dystonia: A consensus update (2013) (1573)
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. (2001) (1129)
Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
Core assessment program for intracerebral transplantations (CAPIT) (1992) (1042)
Validity and reliability of a rating scale for the primary torsion dystonias (1985) (997)
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein (1997) (994)
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it (1992) (978)
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. (2009) (965)
Description of Parkinson's Disease as a Clinical Syndrome (2003) (914)
Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole (1999) (673)
Classification of dystonia. (1998) (666)
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
Tolcapone: COMT inhibition for the treatment of Parkinson's disease. (1998) (570)
Huntington disease (1979) (568)
Concept and classification of dystonia. (1988) (555)
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity (1992) (464)
Committee. Unified Parkinson’s Disease Rating Scale. (2001) (433)
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population (1995) (431)
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm (1987) (426)
Idiopathic cervical dystonia: Clinical characteristics (1991) (389)
The DYT1 phenotype and guidelines for diagnostic testing (2000) (358)
Development of resistance to botulinum toxin type A in patients with torticollis (2004) (357)
Does levodopa slow or hasten the rate of progression of Parkinson’s disease? (2005) (351)
DLB and PDD boundary issues (2007) (351)
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy (1979) (350)
Levodopa in the treatment of Parkinson's disease. (2006) (341)
Tardive dystonia (1982) (339)
Freezing of gait in PD (2001) (328)
Urate as a predictor of the rate of clinical decline in Parkinson disease. (2009) (324)
Functional brain networks in DYT1 dystonia (1998) (316)
The spectrum of levodopa-induced dyskinesias. (2000) (315)
Chronic manganese intoxication. (1974) (314)
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. (2015) (306)
Clinical characteristics of a family with chromosome 17‐linked disinhibition‐dementia‐ parkinsonism‐amyotrophy complex (1994) (299)
Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis (1990) (292)
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. (2008) (289)
Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis (2010) (289)
Primary sensory symptoms in parkinsonism (1976) (285)
“On‐off” phenomenon with levodopa therapy in parkinsonism (1974) (272)
Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. (2004) (269)
The history of dopamine and levodopa in the treatment of Parkinson's disease (2008) (268)
Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. (1998) (264)
Diagnostic guidelines in central nervous system Whipple's disease (1996) (261)
REGIONAL DISTRIBUTION OF γ‐AMINOBUTYRIC ACID (GABA) IN BRAIN OF THE RHESUS MONKEY * (1968) (260)
The effect of estrogen replacement on early Parkinson’s disease (1999) (258)
Phenomenology and psychopathology related to psychogenic movement disorders. (1995) (256)
Dyskinesia after fetal cell transplantation for parkinsonism: A PET study (2002) (255)
Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (2002) (251)
Human gene for torsion dystonia located on chromosome 9q32-q34 (1989) (249)
Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. (1971) (236)
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. I. An associated sodium-activated transphosphorylation. (1966) (233)
The Washington Heights-Inwood Genetic Study of Essential Tremor: methodologic issues in essential-tremor research. (1997) (233)
Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia) (1988) (228)
Study of movement disorders and brain iron by MR. (1987) (228)
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease (2007) (228)
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions (2008) (226)
Cognitive performance of GBA mutation carriers with early-onset PD (2012) (225)
Delayed-onset dystonia in patients with "static" encephalopathy. (1980) (224)
Freezing phenomenon in patients with parkinsonian syndromes (1997) (224)
Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. (1999) (222)
A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease (1998) (219)
Neurodegeneration and neuroprotection in Parkinson disease (2011) (215)
A pilot trial of high‐dose alpha‐tocopherol and ascorbate in early Parkinson's disease (1992) (213)
Freezing of gait in PD: Prospective assessment in the DATATOP cohort (2001) (211)
Idiopathic dystonia among ashkenazi jews: Evidence for autosomal dominant inheritance (1989) (210)
High dosage anticholinergic therapy in dystonia (1983) (206)
An estimate of the prevalence of dementia in idiopathic Parkinson's disease. (1988) (203)
A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease (1994) (194)
“Tip‐of‐the‐tongue” phenomenon in Parkinson disease (1982) (192)
Dopa‐responsive dystonia (1991) (188)
Torsion dystonia (1986) (187)
Botulinum Toxin Injection for the Treatment of Oromandibular Dystonia (1989) (184)
The nosology and pathophysiology of myoclonus (1981) (183)
The freezing phenomenon in parkinsonism. (1995) (182)
Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease (2004) (177)
Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes (2010) (176)
Association of glucocerebrosidase mutations with dementia with lewy bodies. (2009) (175)
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease (2006) (173)
The varied clinical expressions of dystonia. (1984) (173)
Dyskinesias while awake and periodic movements in sleep in restless legs syndrome (1986) (170)
Idiopathic torsion dystonia linked to chromosome 8 in two mennonite families (1997) (169)
Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation (1994) (169)
Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence (1989) (168)
Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population (2011) (167)
Linkage mapping of dopa–responsive dystonia (DRD) to chromosome 14q (1993) (166)
Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations (2002) (166)
Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa (1996) (164)
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. (2014) (163)
A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy (2000) (161)
Distant effects of local injection of botulinum toxin (1987) (161)
The natural history of embouchure dystonia (2001) (159)
Natural history and treatment of tardive dystonia (1986) (157)
The Unified Myoclonus Rating Scale. (2002) (156)
Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity (1993) (154)
Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse lewy body disease and 34 pathologically confirmed cases of parkinson's disease (1997) (151)
Neuroleptic Malignant syndrome caused by dopamine‐depleting drugs in a patient with Huntington disease (1981) (151)
Spread of symptoms in idiopathic torsion dystonia (1995) (150)
Analysis of open‐label trials in torsion dystonia using high dosages of anticholinergics and other drugs (1988) (149)
Clinical and laboratory characteristics of focal laryngeal dystonia: Study of 110 cases (1988) (147)
The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. (1999) (146)
Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease (2018) (142)
Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32–34 (1990) (138)
Distant effects of locally injected botulinum toxin: A double‐blind study of single fiber EMG changes (1991) (138)
Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. (1999) (137)
Neurotoxicity of levodopa on catecholamine‐rich neurons (1992) (137)
Definition of dystonia and classification of the dystonic states. (1976) (136)
Reliability of a new scale for essential tremor (2012) (136)
Functional neuroanatomy of the basal ganglia (2021) (132)
The medical treatment of Parkinson disease from James Parkinson to George Cotzias (2015) (132)
Electromyographic Findings in Focal Laryngeal Dystonia (Spastic Dysphonia) (1985) (130)
Definition and classification of myoclonus. (1986) (129)
THE ROLE OF SODIUM IONS IN THE ACTIVATION OF ELECTROPHORUS ELECTRIC ORGAN ADENOSINE TRIPHOSPHATASE. (1963) (129)
Principles and practice of movement disorders (2011) (127)
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. (2010) (123)
A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus (2001) (121)
Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations (2013) (121)
Evidence-based guideline: Treatment of tardive syndromes (2013) (118)
Physiologic and pathologic tremors. Diagnosis, mechanism, and management. (1980) (117)
Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. (1996) (117)
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. V. Phosphorylation by adenosine triphosphate-32P. (1968) (116)
Tardive akathisia: An analysis of clinical features and response to open therapeutic trials (1989) (116)
Clinical correlates of action tremor in Parkinson disease. (2001) (113)
Neuropathology of lubag (x‐linked dystonia parkinsonism) (1993) (111)
Sodium-potassium-activated adenosine triphosphatase of Electrophorus electric organ. II. Effects of N-ethylmaleimide and other sulfhydryl reagents. (1966) (111)
Effect of High Doses of Dietary Vitamin E on the Concentrations of Vitamin E in Several Brain Regions, Plasma, Liver, and Adipose Tissue of Rats (1988) (110)
Fluctuations of disability in Parkinson's disease: pathophysiology (1981) (110)
Oral and genital pain syndromes in Parkinson's disease (1996) (110)
Familial aggregation of early‐ and late‐onset Parkinson's disease (2003) (108)
The natural history and treatment of acquired hemidystonia: report of 33 cases and review of the literature (2002) (108)
Speech dysfunction in early Parkinson's disease (1995) (107)
Is levodopa toxic? (1996) (107)
Advances in Neurochemistry, Vol. (1979) (105)
Spontaneous remissions in spasmodic torticollis (1986) (105)
Use of intrathecal baclofen in the treatment of patients with dystonia. (1996) (103)
Abductor laryngeal dystonia: A series treated with botulinum toxin (1992) (103)
Should Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment (1984) (102)
Case-control study of the parkin gene in early-onset Parkinson disease. (2006) (101)
Benefits and Risks of Pharmacological Treatments for Essential Tremor (2003) (99)
Subthalamic nucleus stimulation in advanced Parkinson’s disease: blinded assessments at one year follow up (2004) (99)
Delayed‐onset dystonia due to perinatal or early childhood asphyxia (1991) (98)
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A (1993) (97)
Huntington's disease–like 2 (HDL2) in North America and Japan (2004) (97)
Considerations in the management of parkinsonism (1978) (95)
Long‐term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa‐responsive dystonia (1992) (94)
The clinical spectrum of posthypoxic myoclonus (2000) (94)
Pilot association study of the β‐glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity (2005) (94)
Botulinum toxin (BOTOX) for the treatment of "spastic dysphonia" as part of a trial of toxin injections for the treatment of other cranial dystonias. (1986) (91)
Evaluation of the pull test technique in assessing postural instability in Parkinson’s disease (2004) (91)
Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint (1999) (90)
Agreement among movement disorder specialists on the clinical diagnosis of essential tremor (1997) (90)
Dopa‐responsive dystonia (1990) (89)
Accuracy of family history data on Parkinson’s disease (2003) (88)
Contribution of aging to the severity of different motor signs in Parkinson disease. (2005) (88)
Levodopa therapy for Parkinson disease (2016) (88)
Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm (2018) (88)
Methylphenidate treats apathy in Parkinson's disease. (2002) (87)
Mental effects of high-dosage levodopa. (1971) (87)
Dominantly inherited restless legs with myoclonus and periodic movements of sleep: a syndrome related to the endogenous opiates? (1986) (86)
An open trial of high-dosage antioxidants in early Parkinson's disease. (1991) (85)
3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatum (1982) (85)
Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. (1990) (85)
Genetic mapping of “Lubag” (X‐linked dystonia‐parkinsonism) in a filipino kindred to the pericentromeric region of the X chromosome (1991) (84)
Teaching tape for the motor section of the unified Parkinson's disease rating scale (1995) (84)
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside (2020) (83)
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. (2014) (82)
Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation (2000) (80)
Reliability of patient completion of the historical section of the unified Parkinson's disease rating scale (1996) (80)
Mental and Behavioral Dysfunction in Movement Disorders (2003) (80)
Adductor laryngeal dystonia (spastic dysphonia): Treatment with local injections of botulinum toxin (Botox) (1989) (79)
Diagnostic criteria for dystonia in DYT1 families (2002) (79)
Negative Motor Phenomena (1995) (79)
Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease (2001) (78)
Classification of movement disorders (2011) (78)
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. (2010) (78)
Sleep episodes in Parkinson's disease: A wake‐up call (2000) (78)
Analysis of an early‐onset Parkinson's disease cohort for DJ‐1 mutations (2004) (78)
How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? (2008) (77)
Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease (2015) (76)
The characterization and outcome of stereotypic movements in nonautistic children (1997) (76)
Mendelian randomization of serum urate and parkinson disease progression (2014) (76)
Strokes and ulcerative colitis (1978) (76)
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline (2006) (74)
Manganic encephalopathy due to “ephedrone” abuse (2007) (74)
Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease (2012) (73)
Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. (1983) (72)
Emerging topics in FXTAS (2014) (71)
Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. (1979) (71)
Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease (2015) (70)
Ascorbic acid protects against levodopa‐induced neurotoxicity on a catecholamine‐rich human neuroblastoma cell line (1993) (70)
Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium. (1997) (69)
Non-chromaffin tissue plus nerve growth factor reduces experimental parkinsonism in aged rats (1988) (69)
Treatment of drug-induced psychosis in Parkinson's disease with clozapine. (1993) (69)
Psychogenic dystonia. (1988) (68)
A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. (2000) (68)
The Endogenous Toxin Hypothesis of the Etiology of Parkinson's Disease and a Pilot Trial of High‐Dosage Antioxidants in an Attempt to Slow the Progression of the Illness (1989) (68)
Normal pressure hydrocephalus and hypertensive cerebrovascular disease. (1974) (67)
Teaching program for the movement disorder society‐sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS‐UPDRS) (2010) (67)
Tetrabenazine induces acute dystonic reactions (1985) (66)
Rasagiline improves quality of life in patients with early Parkinson's disease (2006) (66)
A study of idiopathic torsion dystonia in a non‐Jewish family (1994) (66)
Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain (1989) (66)
Chronic levodopa or pergolide administration induces down‐regulation of dopamine receptors in denervated striatum (1984) (65)
The phenomenology of tics (1986) (65)
MCARDLE'S DISEASE. HEREDITARY MYOPATHY DUE TO ABSENCE OF MUSCLE PHOSPHORYLASE. (1963) (64)
SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease (2019) (64)
Baclofen in the treatment of idiopathic dystonia in children (1992) (64)
Paroxysmal non-kinesigenic dystonia. (1988) (63)
Sporadic and familial parkinsonism and motor neuron disease (1973) (63)
Adverse Effects of Levodopa in Parkinson’s Disease (1989) (63)
Levodopa-Induced Neurotoxicity (1997) (63)
Exclusion of the DYT1 locus in familial torticollis (1996) (62)
Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD (2003) (62)
Delayed-onset cerebellar syndrome. (1996) (61)
Parkinsonism and motor neuron diseases: Twenty‐seven patients with diverse overlap syndromes (2010) (61)
Dystonia: a disorder often misdiagnosed as a conversion reaction. (1978) (60)
Movement disorders of the larynx (1992) (60)
A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease (2008) (60)
The role of bromocriptine in the treatment of parkinsonism (1979) (59)
Magnetic resonance imaging of dystonic states. (1988) (59)
Outcome of selective ramisectomy for botulinum toxin resistant torticollis (1998) (58)
Essential tremor-plus: a controversial new concept (2019) (58)
Systemic Therapy of Dystonia (1987) (57)
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. (1995) (57)
Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover (1976) (56)
Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain (2014) (56)
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. (2009) (56)
Parkinsonian features of eight pathologically diagnosed cases of diffuse lewy body disease (1995) (56)
Alpha tocopherol in CSF of subjects taking high‐dose vitamin E in the DATATOP study (1998) (56)
Parkinson's disease: 10 years of progress, 1997–2007 (2010) (56)
Response to botulinum toxin F in seronegative botulinum toxin A—resistant patients (1996) (55)
A new look at levodopa based on the ELLDOPA study. (2006) (55)
Correlates of early disability in Huntington's disease (1986) (55)
Treatment of vascular hemiballism and hemichorea (1977) (54)
STABILITY OF ENZYMES IN POST‐MORTEM RAT BRAIN 1 (1976) (54)
Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: Review and technical aspects (1992) (54)
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease (2010) (53)
Adult onset idiopathic torsion dystonia is excluded from the DYT 1 region (9q34) in a Swedish family. (1995) (53)
Intrathecal baclofen in the treatment of dystonic storm (1998) (53)
Long‐term evaluation of amantadine and levodopa combination in parkinsonism by double‐blind crossover analyses (1975) (53)
Clinical variants of idiopathic torsion dystonia. (1989) (53)
The nosology of tardive syndromes (2018) (52)
Speech Dysfluency Exacerbated by Levodopa in Parkinson's Disease (2001) (52)
The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. (1998) (51)
Diagnosis and management of pergolide‐induced fibrosis (2004) (51)
Regional distribution of choline acetylase in the brain of the rhesus monkey. (1968) (51)
Cutaneous electromyographic silent period findings in brachial dystonia (1996) (51)
Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease (2014) (51)
Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. (1988) (50)
3‐O‐Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway (1982) (50)
A longitudinal program for biomarker development in Parkinson's disease: A feasibility study (2009) (50)
Phenotypic expression of X‐linked dystonia‐parkinsonism (lubag) in two women (1993) (50)
Biochemistry of the basal ganglia. (1976) (49)
Olfaction in Parkin heterozygotes and compound heterozygotes (2010) (49)
Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats (1991) (49)
Oral and genital tardive pain syndromes (1994) (49)
Biochemical properties of monoamine-rich human neuroblastoma cells (1989) (47)
Meige syndrome: primary and secondary forms. (1988) (47)
The inv dup(l5) syndrome: A clinically recognizable syndrome with altered behavior, mental retardation, and epilepsy (1997) (46)
Botulinum toxin injections for lingual dystonia (1991) (46)
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method. (2008) (46)
Comparative Correlative Neuroanatomy of the Vertebrate Telencephalon (1983) (46)
Hereditary essential myoclonus in a large norwegian family (1991) (45)
Selegiline and mortality in Parkinson's disease (1996) (45)
Posthypoxic action myoclonus: literature review update. (1986) (45)
Blepharospasm: a form of focal dystonia. (1988) (45)
Catechol-O-methyltransferase and Parkinson's disease. (1984) (44)
Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. (2018) (44)
“Psychogenic Movement Disorders”: They Are What They Are (2014) (44)
Focal task‐specific dystonia induced by peripheral trauma (2000) (44)
Paroxysmal dystonic choreoathetosis in a patient with familial ataxia (1982) (43)
Normalization of brain serotonin by L‐tryptophan in levodopa‐treated rats (1975) (43)
A case of post-traumatic tic syndrome. (1982) (43)
Levodopa: 50 years of a revolutionary drug for Parkinson disease (2015) (42)
Intrathecal baclofen in the treatment of dystonia. (1998) (42)
Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD (2012) (42)
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. (2019) (42)
ASSOCIATION OF TYROSINE HYDROXYLASE WITH SYNAPTIC VESICLES IN BOVINE CAUDATE NUCLEUS 1 (1969) (42)
Controversies in the therapy of Parkinson's disease. (1996) (41)
Mirtazapine in Parkinsonian tremor. (2002) (41)
Antiparkinsonian therapies and brain mitochondrial complex I activity (1995) (41)
Lack of familial aggregation of Parkinson disease and Alzheimer disease. (2004) (41)
A therapeutic approach to tardive dyskinesia. (1985) (40)
The effect of chronic L-dopa administration on supersensitive pre- and postsynaptic dopaminergic receptors in rat brain. (1982) (40)
FETAL TISSUE TRANSPLANATION IN PARKINSON'S DISEASE (1998) (40)
The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. (2018) (40)
Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence (1991) (40)
Double-blind evaluation of trihexyphenidyl in dystonia. (1983) (39)
Clinicopathological characteristics of freezing of gait in autopsy‐confirmed Parkinson's disease (2015) (39)
Painful dystonic spasms in Parkinson's disease. (1984) (38)
Cerebral hypoxia and its consequences. (1979) (38)
Polymerase chain reaction—based detection of Tropheryma whippelii in central nervous system Whipple's disease (1997) (38)
Pharmacokinetics of trihexyphenidyl after short‐term and long‐term administration to dystonic patients (1985) (38)
Exclusion of the DYT1 locus in a non‐Jewish family with early‐onset dystonia (1994) (38)
Acute toxic psychosis from suicidal overdosage of amantadine. (1971) (37)
Differential diagnosis of tremors. (1972) (37)
Psychogenic movement disorders and other conversion disorders (2011) (36)
The relation between depression and parkin genotype: the CORE-PD study. (2011) (36)
Translation of Oppenheim's 1911 paper on dystonia (2013) (36)
Post-anoxic action myoclonus: improvement with valproic acid. (1978) (35)
Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation (2007) (35)
Antimuscarinic drugs in the treatment of movement disorders. (1990) (35)
Dominantly inherited, early‐onset parkinsonism (1993) (35)
Diagnosing Parkinson's disease using videotaped neurological examinations: Validity and factors that contribute to incorrect diagnoses (2002) (35)
Closing the tau loop: the missing tau mutation. (2015) (34)
Distant effects of locally injected botulinum toxin: incidence and course. (1988) (34)
Practical management of dystonia. (1984) (33)
Tolcapone (1998) (33)
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. (1983) (33)
Secondary dystonia and the DYTI gene (1997) (33)
Treatment of Tardive Dyskinesia: Use of Dopamine‐Depleting Agents (1983) (33)
The clinical spectrum of motor tics. (1982) (33)
Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. (1991) (33)
Generalized Dystonia: Concept and Treatment (1986) (33)
Overview, history, and classification of myoclonus. (2002) (32)
SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease (2016) (31)
Therapeutic trial with glycine in myoclonus (1988) (31)
Fetal-tissue transplants in Parkinson's disease. (1992) (30)
Dopamine receptors in the denervated striatum: further supersensitivity by chronic haloperidol treatment (1983) (30)
Chronic lithium administration has no effect on haloperidol-induced supersensitivity of pre- and postsynaptic dopamine receptors in rat brain (1982) (30)
Welcome news about levodopa, but uncertainty remains (1998) (30)
Clonazepam, Haloperidol, and Clonidine in Tic Disorders (1988) (30)
Studies of somatostatin-induced barrel rotation in rats (1983) (30)
Sequential parkinsonism and chorea following "mild" inluenza. (1976) (30)
Increase in brain serotonin produced by bromocryptine (1975) (30)
Dystonia in a patient with deletion of 18q (1995) (30)
Torsion Dystonia: Clinical Spectrum and Treatment (1982) (29)
Adaptation of Stability during Perturbed Walking in Parkinson’s Disease (2017) (29)
Neurochemical findings in neuroacanthocytosis (1988) (29)
Opioid responsiveness in patients with neuroleptic‐induced akathisia (1986) (29)
Problems in Parkinson's disease (1981) (29)
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. (2006) (29)
Dopa‐responsive dystonia due to mild tyrosine hydroxylase deficiency (2004) (29)
A reliable and simple method for simultaneous determination of DOPA and 3-O-methyldopa in plasma and brain. (1972) (29)
Neurotensin interacts with dopaminergic neurons in rat brain (1983) (28)
Analysis of the clinical course of non‐Jewish, autosomal dominant torsion dystonia (1986) (28)
High dosage anticholinergic therapy in dystonia. (1983) (28)
Differential changes in 125I-LSD-labeled 5-HT-2 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN): evidence from autoradiographic studies (1987) (28)
French horn embouchure dystonia (1999) (27)
Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders (1994) (27)
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside (2020) (27)
Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center (2015) (26)
Torsion dystonia genes in two populations confined to a small region on chromosome 9q32-34. (1991) (26)
The genetics of idiopathic torsion dystonia. (1991) (25)
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study (2010) (25)
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease (2020) (25)
Movement disorder in reflex sympathetic dystrophy: A case proven to be psychogenic by surveillance video monitoring (1997) (25)
Continous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease (1987) (25)
Comprar Principles and Practice of Movement Disorders, 2nd Edition | Mark Hallett MD | 9781437723694 | Saunders (2011) (25)
Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson's disease among Ashkenazi Jews (2013) (25)
Experience with tranylcypromine in early Parkinson's disease. (1998) (25)
Sins of Commission (1983) (25)
The iminodipropionitrile (IDPN) model of persistent spasmodic dyskinesias: regional serotonin metabolism in rat brain (1988) (24)
Myoclonus in complex regional pain syndrome (2009) (24)
Clonazepam-induced up-regulation of serotonin1 and serotonin2 binding sites in rat frontal cortex. (1986) (24)
The history of parkinsonism (1989) (24)
Therapeutic trials in Meige syndrome. (1983) (24)
Preoperative response to levodopa is the best predictor of transplant outcome (2004) (24)
Modulation of parkinsonian tremor by radial nerve palsy (1994) (24)
Tics in a patient with Parkinson's disease (1986) (23)
Prin & Prac of Movement Disorders (2007) (23)
THE EFFECT OF NEUROTENSIN ON DOPAMINERGIC NEURONS IN RAT BRAIN * (1982) (23)
Long-term treatment with levodopa in a family with autosomal dominant torsion dystonia. (1988) (23)
Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations (2020) (23)
Movement disorder of RSD (1990) (23)
Relationship of clinical efficacy to postmortem-determined anatomic subthalamic stimulation in Parkinson syndrome. (2007) (23)
What is it? case 1, 1996: Rapidly progressive parkinsonism, incontinence, impotency, and levodopa‐induced moaning in a patient with multiple myeloma (1996) (23)
Genetic markers of Restless Legs Syndrome in Parkinson disease. (2015) (22)
Reaction time and movement time after embryonic cell implantation in Parkinson disease. (2004) (22)
Transient dystonia as a complication of varicella. (1987) (22)
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson disease (2021) (22)
Newer medical treatment in parkinsonism. (1970) (22)
Experimental therapeutics of movement disorders. (1983) (22)
Autoradiography of dopamine receptors and dopamine uptake sites in the spontaneously hypertensive rat (1990) (21)
Adductor laryngeal breathing dystonia in a patient with lubag (X‐linked dystonia‐parkinsonism syndrome) (1994) (21)
Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. (2002) (21)
Waht is it? Case 1, 1990: Progressive unilateral rigidity, bradykinesia, tremulousness, and apraxia, leading to fixed postural deformity of the involved limb (1990) (21)
Restless legs syndrome in Chinese elderly people of an urban suburb in Shanghai: a community-based survey. (2012) (21)
Common and rare GCH1 variants are associated with Parkinson's disease (2019) (21)
Botulinum Toxin for the Treatment of Movement Disorders (2012) (21)
Movement disorders 4 (2010) (21)
The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum. (1985) (20)
Recent Advances in EEG and EMG Data Processing (1983) (20)
A geste antagoniste device to treat jaw‐closing dystonia (1999) (20)
REGIONAL DISTRIBUTION OF SODIUM‐POTASSIUM ACTIVATED ADENOSINE TRIPHOSPHATASE IN THE BRAIN OF THE RHESUS MONKEY * (1968) (20)
Electroencephalographic studies of chlorpromazine methiodide and somatostatin-induced barrel rotation in rats (1983) (20)
Choline acetyltransferase activity of the principal vestibular nuclei of rat, studied by micropunch technique (1985) (20)
Receptor autoradiography of μ and δ opioid peptide receptors in spontaneously hypertensive rats (1991) (19)
3-O-methyl metabolites of catecholamines: automated fluorometric assay and their plasma levels in patients receiving levodopa and carbidopa. (1974) (19)
Levodopa‐induced dyskinesias in autopsy‐proven cortical‐basal ganglionic degeneration (2000) (19)
Treatment of Torticollis with Injections of Botulinum Toxin (1987) (18)
Chlorpromazine methiodide acts at the vestibular nuclear complex to induce barrel rotation in the rat (1983) (18)
Psychogenic parkinsonism. (1995) (18)
Development of Antibodies to Botulinum Toxin Type A in Patients with Torticollis Treated with Injections of Botulinum Toxin Type A (1993) (18)
Hemiparkinsonism–hemiatrophy syndrome may mimic early‐stage cortical–basal ganglionic degeneration (1992) (18)
Relationship between Dose of Vitamin E Administered and Blood Level a (1989) (18)
Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene (2007) (18)
Chlorpromazine methiodide-induced barrel rotation: an antimuscarinic effect (1982) (18)
Inheritance of idiopathic torsion dystonia among Ashkenazi Jews. (1988) (18)
TARDIVE DYSTONIA AND INAPPROPRIATE USE OF NEUROLEPTIC DRUGS (1982) (18)
Freezing Phenomenon, the Fifth Cardinal Sign of Parkinsonism (1998) (18)
The gene for familial dystonia with myoclonic jerks responsive to alcohol is not located on the distal end of 9q (1994) (18)
Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop (1998) (18)
Inpatient treatment for functional neurologic disorders. (2016) (17)
Movement disorders fellowship training program at Columbia University Medical Center in 2001–2002 (2006) (17)
Movement disorders and pregnancy. (1994) (17)
Thin-layer chromatography for the separation of nucleotides (1965) (17)
Role of SCA2 mutations in early‐ and late‐onset dopa‐responsive parkinsonism (2002) (17)
Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration. (1979) (17)
Treatment of choreic movements with perphenazine. (1972) (17)
The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study (2015) (17)
Cerebellar control of catecholaminergic activities implications for drug therapy of movement disorders. (1979) (17)
Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain — Possible mechanisms of milacemide antimyoclonic property in the p,p′-DDT-induced myoclonus (1989) (16)
Biotin-responsive encephalopathy with myoclonus, ataxia, and seizures. (1986) (16)
The role of the DYT1 gene in secondary dystonia. (1998) (16)
Chapter 1 – The Role of Levodopa and Catechol-O-Methyltransferase Inhibitors (2005) (16)
Oculofacial-skeletal myorhythmia in Whipple's disease. (1997) (16)
Myoclonus and Paroxysmal Dyskinesias (2002) (16)
An early description of dystonia: translation of Schwalbe's thesis and information on his life. (1988) (16)
Pergolide therapy for Parkinson's disease (1984) (15)
Motor and Vocal Tics (2004) (15)
Electrophorus Adenosine Triphosphatase: Sodium-Activated Exchange after N-Ethyl Maleimide Treatment (1964) (15)
Interaction between bromocriptine and levodopa (1977) (15)
The Autosomal Dominant Dystonias (1992) (15)
Essential myoclonus. (1986) (15)
Classical Transmitters and Transmitter Receptors in the CNS, Part II. (Handbook of Chemical Neuroanatomy, Vol 3) (1985) (15)
Clonazepam-induced up-regulation of serotonin1 binding sites in frontal cortex of rat (1985) (15)
Synthesis and dopaminergic activity of 3-(3,4-dihydroxyphenyl)-1-n-propylpyrrolidine hydrobromide. (1984) (15)
Biochemistry and the Central Nervous System ed 3. (1967) (15)
Carbamazepine in torsion in dystonia. (1976) (15)
Pergolide treatment in parkinsonism. (1983) (15)
Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease (2021) (15)
Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade (1986) (15)
Cerebellar tremor: clinical aspects (1984) (14)
Treatment issues in psychogenic-neuropsychiatric movement disorders. (2005) (14)
Chapter 25 – Psychogenic movement disorders: Phenomenology, diagnosis, and treatment (2011) (14)
Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine. (1983) (14)
Drug treatment of hyperkinetic movement disorders. (1987) (14)
Tardive Akathisia: Motor Phenomena and Treatment (1987) (14)
Designing Clinical Trials for Dystonia (2013) (14)
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 (2018) (14)
Partial attenuation of chronic fluphenazine-induced changes in regional monoamine metabolism by D-α-tocopherol in rat brain (1991) (14)
Serum trihexyphenidyl levels in the treatment of torsion dystonia (1985) (14)
A practical approach to remote longitudinal follow‐up of Parkinson's disease: The FOUND study (2014) (14)
Pathologically diagnosed diffuse Lewy body disease and Parkinson's disease. Do the parkinsonian features differ? (1996) (13)
The Biochemical Basis of Neuropharmacology, Ed. 3 (1979) (13)
Intracerebroventricular infusion of dopamine and its agonists in rodents and primates. An experimental approach to the treatment of Parkinson's disease. (1988) (13)
Handbook of movement disorders (1998) (13)
Atypical tremors, rare tremors and unclassified tremors (1984) (13)
Tardive dysphrenia and subjective akathisia. (1979) (13)
Implantation of genetically modified mesencephalic fetal cells into the rat striatum (1992) (13)
Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum. (1982) (13)
Normal pressure hydrocephalus and Parkinson's disease. (1983) (12)
Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain (1984) (12)
Monoamine oxidase inhibitory properties of milacemide in rats. (1989) (12)
Dietary constituents and nitrosamine formation in human saliva. (1978) (12)
Paroxysmal myoclonic dystonia with vocalisations. (1987) (12)
Clinical Aspects of Parkinson Disease (2008) (12)
Psychopharmacology of Anticonvulsants (1983) (12)
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. (1988) (12)
Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders (1993) (12)
Case 3, 1991: Moaning in a man with Parkinsonian signs (1991) (12)
373. Double-blind controlled trial of embryonic dopaminergic tissue transplants in advanced Parkinson’s disease (2000) (12)
Molecular genetics of an autosomal dominant form of torsion dystonia. (1988) (11)
Resistance of SOD-Transgenic Mice to Oxidative Stress (1992) (11)
Glycine involvement in DDT‐induced myoclonus (1988) (11)
Homovanillic acid: entry rate kinetics for transfer from plasma to cerebrospinal fluid. (1974) (11)
Chapter 23 – The Paroxysmal Dyskinesias (1994) (11)
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts (2009) (11)
Management of tardive dyskinesia (1988) (11)
Huntington's Chorea (1984) (11)
Chapter 19 – The tardive syndromes: Phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromes (2007) (11)
The DYT1 mutation and nonfamilial primary torsion dystonia. (2001) (11)
Variants in the Niemann–Pick type C gene NPC1 are not associated with Parkinson's disease (2020) (10)
Comprar Psychogenic Movement Disorders And Other Conversion Disorders + Dvd | Mark Hallett | 9781107007345 | Cambridge University Press (2011) (10)
Does personality change as a result of fetal tissue transplantation in the brain? (2003) (10)
The Pharmacological Basis of Therapeutics. (1966) (10)
Peripherally induced EMG silent periods. Normal physiology and disorders of motor control. (1995) (10)
Reply to “ITD in Ashkenazi Jews — genetic drift or selection?” (1995) (10)
Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease (2020) (10)
Pharmacologic evaluation of dopaminergic receptor blockade by metoclopramide. (1986) (10)
Safety of IPX066, an extended release carbidopa–levodopa formulation, for the treatment of Parkinson’s disease (2015) (10)
Functional electrical stimulation for the treatment of lower extremity dystonia. (2012) (10)
More on myoclonus in alzheimer disease (1980) (10)
LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease (2020) (10)
Letter: Pain, paresthesia and parkinsonism. (1975) (10)
A CASE WITH GILLES DE LA TOURETTE'S SYNDRSOME: RECURRENT REFRACTORINESS TO HALOPERIDOL, AND UNSUCCESSFUL TREATMENT WITH L-DOPA (1971) (10)
Generalized chorea in an infant with semilobar holoprosencephaly. (1995) (9)
Paroxysmal kinesigenic dyskinesia in infancy (1999) (9)
Letters to the editor (1990) (9)
Clinical overview and phenomenology of movement disorders (2021) (9)
L-DOPA (L-3,4-dihydroxyphenylalanine) uptake by human red blood cells. (1981) (9)
Analysis of common and rare VPS13C variants in late-onset Parkinson disease (2020) (9)
Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease (2021) (9)
Changes in adrenal dopamine concentration after metyrapone or ACTH administration: implications for the in vivo regulation of dopamine beta-hydroxylase by glucocorticoids. (1977) (9)
Biallelic and monoallelic variants in PLXNA1 are implicated in a novel neurodevelopmental disorder with variable cerebral and eye anomalies (2021) (9)
Movement Disorder Emergencies: Diagnosis and Treatment (2022) (9)
Two-hundred Years Later: Is Parkinson's Disease a Single Defined Entity? (2017) (9)
Lack of benefit from cervical cord stimulation for dystonia. (1985) (9)
Meige syndrome a review of 31 cases (1981) (8)
The spectrum of levodopa-induced dyskinesias. Discussion (2000) (8)
Chronic treatment with bromocriptine induces behavioral supersensitivity in rats. (1986) (8)
Lithium interferes with reserpine‐induced dopamine depletion (1983) (8)
Is dopamine a neurohormone of the adrenal medulla? (1977) (8)
The Assessment and therapy of parkinsonism (1990) (8)
Neurodegeneration and neuroprotection in Parkinson disease (2004) (8)
Treatment of tardive dyskinesia with combined reserpine and alpha-methyltyrosine. (1978) (8)
Reductions in pain thresholds and morphine analgesia following intracerebroventricular parachlorophenylalanine (1984) (8)
GABA and the Basal Ganglia (1983) (8)
The Use of Amantadine in Parkinson's Disease and other Akinetic-Rigid Disorders (2004) (7)
Pharmacological differentiation of tremor (1984) (7)
Posttraumatic-Delayed Cerebellar Syndrome-Reply (1996) (7)
High-dosage vitamin E supplementation and all-cause mortality. (2005) (7)
Unilateral Parkinson's disease and contralateral tardive dyskinesia: a unique case with successful therapy that may explain the pathophysiology of these two disorders. (1980) (7)
Synthesis and dopaminergic activity of trans-4-methyl-3-phenylpyrrolidines (1987) (7)
Chapter 74 – Parkinsonism (2003) (7)
ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONISM (1979) (7)
Botulinum toxin for the treatment of oromandibulolingual omd dystonia (1989) (7)
Neuropathological correlation supports automated image-based differential diagnosis in parkinsonism (2021) (7)
Genetic linkage analysis in primary torsion dystonia (1984) (7)
WHAT ARE THE BASAL GANGLIA DISEASES? (1990) (7)
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. 1994. (2001) (7)
Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses. (1975) (7)
“Complex” dystonia is not a category in the new 2013 consensus classification (2016) (7)
MCARDLE'S DISEASE: HEREDITARY MYOPATHY DUE TO ABSENCE OF MUSCLE PHOSPHORYLASE. (1963) (7)
Chapter 1 – Clinical overview and phenomenology of movement disorders (2011) (7)
Future strategies for the treatment of Parkinson's disease. (1993) (7)
Molecular genetic analysis of Lubag. (1998) (6)
The effect of selective lesions on vestibular nuclear complex choline acetyltransferase activity in the rat (1985) (6)
Chapter 4 – Parkinsonism: Clinical Features and Differential Diagnosis (2007) (6)
Fluorometric determination of homovanillic acid in the presence of other acid metabolites of catecholamines 1 (1973) (6)
Reply to: Psychogenic movement disorders: What's in a name? (2014) (6)
COVID-19 manifestations in people with Parkinson’s disease: a USA cohort (2021) (6)
Fetal tissue transplantation [correction of transplanation] in Parkinson's disease. (1998) (6)
Electroconvulsive treatment and haloperidol: Effects on pre- and postsynaptic dopamine receptors in rat brain (2004) (6)
Tardive dyskinesia may be only akathisia. (1978) (6)
Stimulus Sensitive Foot Myoclonus: A Clue to Coeliac Disease (2019) (6)
Analysis of common and rare VPS13C variants in late onset Parkinson disease (2019) (6)
Autoradiographic evidence of [3H]neurotensin binding changes in discrete regions of brain in the rat model of persistent spasmodic dyskinesia induced by iminodipropionitrile (1989) (6)
Symposium on the Etiology, Pathogenesis, and Prevention of Parkinson's Disease (1988) (6)
Newer drugs for posthypoxic action myoclonus: observations from a well-studied case. (1986) (6)
ESSENTIAL TREMOR. AUTHOR'S REPLY (1992) (6)
Addressing non-motor impairments in Parkinson's disease: The new version of the UPDRS (2005) (6)
A new society, a new journal, and a new medium (1986) (5)
Chapter 16 – Hypokinesia and Hyperkinesia (2007) (5)
An Overview of Novel Therapies for Parkinson's Disease (1997) (5)
Woman with a 26‐year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexes (2004) (5)
The tardive syndromes: Phenomenology, concepts on pathophysiology, & treatment (1992) (5)
A new eponym (1994) (5)
Acetylcholinesterase activity in patients with torsion dystonia. Measurement in erythrocyte membranes. (1985) (5)
Dopamine: a sensitive automated assay and examples of levodopa therapy. (1975) (5)
Case 2, 1991: Unusual tremor, myoclonus, and a limping gait (1991) (5)
Nervous System Toxicology (1983) (5)
Moral, Ethical, and Legal Issues in the Neurosciences (1983) (5)
Fluctuations of disability in parkinsons disease patho physiology (1982) (5)
Lesions Associated with the Classic Triad of Parkinsonian Motor Features (2010) (5)
The Diagnosis and Treatment of Tardive Disorders (1998) (5)
Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa (1982) (5)
An evaluation of sustained postural abnormalities in rats induced by intracerebro-ventricular injection of chlorpromazine methiodide or somatostatin as models of dystonia. (1988) (5)
Presynaptic inhibition of dopamine synthesis in rat striatum: effects of chronic dopamine depletion and receptor blockade (1985) (5)
Chapter 12 – Dystonia: Phenomenology, classification, etiology, pathology, biochemistry, and genetics (2011) (5)
Regional changes in brain 5-HT1A serotonin receptors in the rat model of persistent spasmodic dyskinesias induced by iminodipropionitrile (1989) (5)
Tardive dystonia. (1988) (5)
Positron Emission Tomography and Embryonic Dopamine Cell Transplantation in Parkinson’s Disease (2005) (4)
Chapter 5 – Current concepts on the etiology and pathogenesis of Parkinson disease (2007) (4)
dl-threo-DOPS as a precursor of noradrenaline (1985) (4)
Phenothiazine‐induced dystonias (1984) (4)
Charcot, the clinician: The Tuesday Lessons: Excerpts from nine case presentations on general neurology delivered at the Salpêtrière hospital in 1887–88 by Jean‐Martin Charcot. Translated with commentary by Christopher G. Goetz. Raven press, New York, 223, illustrated, $56.00, 1987 (1989) (4)
Progress in Clinical Neurophysiology, Vols. 4 and 5 (1979) (4)
The effect of intracerebroventricular infusion of (+)‐4‐propyl‐9‐hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency (1987) (4)
Response of Essential Tremor to Treatment with Primidone (1987) (4)
Further experiences with low doses of bromocriptine in Parkinson's disease. (1980) (4)
Professor C. David Marsden (1999) (4)
Synthesis and Dopaminergic Activity of trans-4-Methyl-3-phenylpyrrolidines. (1988) (4)
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease (2022) (4)
Chapter 10 – Parkinsonism-Plus Syndromes and Secondary Parkinsonian Disorders (2007) (4)
What is it? Case 1, 1987: Unusual tremors, bradykinesia, and cerebral lucencies (1987) (4)
Dopamine. Advances in Biochemical Psychopharmacology, Vol. 19 (1979) (4)
Receptor autoradiography of mu and delta opioid peptide receptors in spontaneously hypertensive rats. (1991) (4)
Chapter 9 – Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders (2011) (4)
The protein synthesis inhibitor, anisomycin, causes exacerbation of the iminodipropionitrile-induced spasmodic dyskinetic syndrome in rats (1989) (4)
Lithium in the "on-off" phenomenon. (1983) (4)
24. Psychogenic Movement Disorders (2012) (4)
Regional and subcellular distribution of tyrosine hydroxylase. (1968) (4)
Movement Disorders and Sleep (2013) (4)
Movement Disorders 4: Blue Book Neurology Series (2010) (4)
Symposium I: Therapeutic controversies in movement disorders. (1979) (4)
A novel exaggerated "spino-bulbo-spinal like" reflex of lower brainstem origin. (2019) (4)
Lithium does not interact, with haloperidol in the dopaminergic pathways of the rat brain (2004) (4)
Problems in dyskinesias (1981) (4)
What Is the Most Important and Impactful Paper Related to Movement Disorder Therapy Published in the 20th Century? (2021) (4)
Acetylcholinesterase and butyrylcholinesterase in cerebrospinal fluid from patients with dystonia. (1988) (4)
Animal Models of Parkinson's Disease to Aid Drug Discovery and Development (2008) (3)
New version of the UPDRS: Development methods and working document for field testing (2005) (3)
Little effect of dimethyl sulfoxide on blood-brain barrier to dopamine (1984) (3)
The Place of Placebos/Sham Surgery in Clinical Trials (2002) (3)
Chapter 6 – Medical treatment of Parkinson disease (2007) (3)
Movement Disorders: Overview (2010) (3)
Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1 (2021) (3)
Basal Ganglia Gliosis in a Case of Rapid‐Onset Dystonia‐Parkinsonism (DYT12) with a Novel Mutation in ATPase 1A3 (ATP1A3) (2016) (3)
Essential Tips for Videotaping a Movement Disorders Patient Encounter (2015) (3)
A 32‐year‐old man with progressive spasticity and parkinsonism (1999) (3)
New approaches in the management of hyperkinetic movement disorders. (1977) (3)
Chapter 24 – Wilson disease (2011) (3)
What is it? Case 1, 1988. Head tilt in a young girl associated with neck pain and limitation of neck movement (1988) (3)
[Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases]. (1988) (3)
ADS-5102 provided reduction in motor complications in Parkinson’s disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2) (2017) (3)
Neuroleptic malignant syndrome caused by dopamine depleting drugs (1982) (3)
Chapter 2 – Motor Control: Physiology of Voluntary and Involuntary Movements (2007) (3)
Chapter 15 – Huntington Disease (2007) (3)
Quantitative autoradiographic changes in 5-[3H]HT-labeled 5-HT1 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN) (1990) (3)
Chapter 24 – Restless Legs Syndrome and Peripheral Movement Disorders (2007) (3)
GABA levels in CSF of neurological patients by high performance liquid chromatography (1980) (3)
Case 1, 1989: Juvenile‐onset parkinsonism, dystonia, and pyramidal tract signs (1989) (3)
Announcing the “Videotapes to the Editor” section (1988) (3)
Severe cervical dystonia in pathologically proven Parkinson's disease and dementia (PDD) (2003) (3)
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. (2020) (3)
Biology and Pathology of Nerve Growth (1983) (3)
Chapter 21 – Ataxia: Pathophysiology and clinical syndromes (2011) (2)
Essential tremor (1992) (2)
The video medium creates new responsibilities and opportunities (1986) (2)
Genetics of Parkinson Disease and Related Diseases (2015) (2)
Correlation of behavioral and biochemical parameters of dopamine d 1 and d 2 receptor activation (1985) (2)
INTRATHECAL BACLOFEN. REPLY (1994) (2)
A Brief Introduction to Movement Disorders (2005) (2)
GLIOBLASTOMA FOLLOWING STEREOTAXIC IMPLANTATION OF AUTOLOGOUS ADRENAL MEDULLA FOR YOUNG-ONSET FAMILIAL PARKINSONISM: AN AUTOPSY CASE (1990) (2)
A semiautomated method for the rapid determination of dopa: comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients. (1982) (2)
Fetal Tissue Transplantation for the Treatment of Parkinson’s Disease (2003) (2)
Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
Delayed-onset dystonia inpatients with"static" (1980) (2)
Serotonin depletion induced by reserpine is attenuated by prophylactic administration of lithium. (1985) (2)
Multiple System Atrophy With Predominant Striatonigral Degeneration and TAR DNA‐Binding Protein of 43 kDa Pathology: An Unusual Variant of Multiple System Atrophy (2019) (2)
Movement disorders 1 and 2 (1995) (2)
Exclusion of autosomal dominant dystonia gene from large regions of chromosomes 11p, 13q, and 21q by multi‐point linkage analysis (1987) (2)
Chapter 11 – Gait Disorders: Pathophysiology and Clinical Syndromes (2007) (2)
Huntington's Disease. Advances in Neurology, Vol. 23 (1980) (2)
Autosomal Dominant Dystonia in a Large North American Family: Clinical Features (1987) (2)
Parkinson disease and related disorders (2020) (2)
Chapter 16 – Tics and Tourette syndrome (2011) (2)
Levodopa provocative test for Huntington's disease. (1980) (2)
Author Response to Comments on "Evidence-Based Guideline: Treatment of Tardive Syndromes" (2013) (2)
Dystomia 3. Summary and conclusions. (1998) (2)
Anticholinergic responsive cyclic myoclonus (2013) (2)
Chapter 3 – Functional Neuroanatomy of the Basal Ganglia (2007) (2)
Anoxic myoclonus in the rat. (1979) (2)
Peripheral movement disorders (2021) (2)
Tourette syndrome. (1996) (2)
Dr. S. A. Kinnier Wilson (1887‐1937) (1988) (2)
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. (1988) (2)
Author response. (2013) (2)
Chapter 21 – Myoclonus: Phenomenology, Etiology, Physiology, and Treatment (2007) (2)
The Muscle Testing Handbook (1987) (2)
Early-Onset, Generalized Dystonia Caused by DYT1 Gene on Chromosome 9q34 (1995) (2)
[Botulinum toxin as a powerful new tool in the treatment of focal dystonia]. (1991) (2)
L-dopa effect in Huntington's chorea. (1972) (2)
Diagnosis and management of pergolide-induced fibrosis. Authors' reply (2005) (2)
Medical treatment of the motor features of Parkinson disease (2021) (2)
Follow‐up of “What is it?” Case 1, 1987 (1988) (2)
Hoehn and Yahr stage 3 and postural stability item in the movement disorder society–unified Parkinson's disease rating scale (2018) (2)
Treatment of vascular hemichorea and hemiballismus with perphenazine. (1974) (2)
Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation: A Pilot Study (2018) (2)
Dopamine beta‐hydroxylase activity in cerebrospinal fluid of idiopathic torsion dystonia (1990) (2)
Letters to the editor (1993) (1)
Walsh and Hoyt's Clinical Neuro‐Ophthalmology, Ed. 4, Vol. 1 (1983) (1)
Deep-brain stimulation extends relief from Parkinson's. Electrodes deep in the brain continue relieving Parkinson's disease symptoms for five years. (2004) (1)
Chapter 10 – Gait disorders: Pathophysiology and clinical syndromes (2011) (1)
Chapter 15 – Chorea, ballism, and athetosis (2011) (1)
Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease (2018) (1)
Chapter 7 – Surgical treatment of Parkinson disease and other movement disorders (2007) (1)
Comprar Movement Disorders 4 Blue Books of Neurology Series, Volume 34 | Anthony H. V. Schapira | 9781416066415 | Saunders (2010) (1)
Manter and Gatz's Essentials of Clinical Neuroanatomy & Neurophysiology, Ed. 6 (1984) (1)
Pharmaceutical industry support of the AAN Annual Meeting: Policies and violation (2002) (1)
Chapter 20 – Myoclonus: Phenomenology, etiology, physiology, and treatment (2011) (1)
Parkinson‐Specific Motor and Mental Disorders‐Role of the Pallidum (1984) (1)
Highlights of the Parkinson's Disease Foundation. (1998) (1)
Chapter 11 – Stiffness syndromes (2011) (1)
Behavioral effects of alpha-benzyl-N-methylphenythylamine (ABNMP), a methamphetamine analog: Inhibition by ketanserin and para-chlorophenylalanine (PCPA) (1988) (1)
The early history of paroxysmal dyskinesias. (2002) (1)
[New therapeutic alternatives in Parkinson disease]. (1987) (1)
Linkage studies in families with dystonia: linkage analysis as a tool to locate and characterize the gene(s) for dystonia. (1988) (1)
Is the thought disorder with oculogyric crisis a feature of tardive akathisia or tardive dysphrenia? (1988) (1)
Chapter 17 – Stereotypies (2011) (1)
Baseline Differences in Long-term Survivors and Nonsurvivors of the Colorado/Columbia Fetal Implant Trial (2021) (1)
Parkinson's Disease (1979) (1)
Placebo surgery in trials of therapy for Parkinson's disease. (2000) (1)
The Extrapyramidal System and Its Disorders. Advances in Neurology, Vol. 24 (1980) (1)
Emerging topics in FXTAS (2014) (1)
Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia. (1990) (1)
POSTTRAUMATIC-DELAYED CEREBELLAR SYNDROME. AUTHORS' REPLY (1996) (1)
Chapter 16 – Chorea, Ballism, Athetosis: Phenomenology and Etiology (2007) (1)
Chapter 8 – Nonmotor Problems in Parkinson Disease (2007) (1)
Letters to the editor (2000) (1)
Chemistry of Learning: Invertebrate Research. (1968) (1)
Association of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's Disease (2020) (1)
Nonmotor problems in Parkinson disease (2021) (1)
Glucocerebrosidase activity in Parkinson disease with and without GBA mutations (S7.003) (2015) (1)
Erratum: Emerging topics in FXTAS (2015) (1)
TARDIVE PAIN. AUTHORS' REPLY (1995) (1)
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort (2023) (1)
[Pathophysiological mechanisms of adverse effects from levodopa therapy]. (1982) (1)
Chapter 26 – Psychogenic Movement Disorders: Phenomenology, Diagnosis, and Treatment (2007) (1)
Intrathecal baclofen (1994) (1)
Gilles de la Tourette Syndrome (1980) (1)
Chapter 4 – Restless Legs Syndrome as a Movement Disorder (2009) (1)
Introducing the “what is it?” section (1986) (1)
Lithium in the “On‐Off” Phenomenon (1983) (0)
Correlation of sodium-potassium-activated adenosine triphosphatase with acetyl cholinesterase of theElectrophorus electric organ (1968) (0)
Treatment of Status Dystonicus (Dystonic Storm) (2019) (0)
Chapter 14 – Treatment of Dystonia (2007) (0)
Parkinson’s gait: when falls become pitfalls (2008) (0)
Iminodiproprionitrile (IDPN) Causes Opiate Mu Receptors in Rat Brain: A Quantitative Auroradiographic Study (1987) (0)
Disorders of the Motor Unit (1983) (0)
Evaluation of dynamic gait stability after a single-session of waist-pull perturbation training in Parkinson’s disease using an Active Tethered Pelvic Assist Device (A-TPAD). (P1.071) (2017) (0)
Association of rare variants in ARSA with Parkinson’s disease (2023) (0)
Chapter 9 – Experimental Models and New, Emerging Therapies for Parkinson Disease (2007) (0)
Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia (1991) (0)
Psychiatry and Neurology 1961-1962 journal review (1963) (0)
Progress in Psychiatry (1901) (0)
Geriatric Neurology (1983) (0)
Cerebral arteritis associated with ulcerative colitis (1979) (0)
Brain Edema (1983) (0)
17.1 – Surgical approaches to the dyskinesias: foreword (1981) (0)
Strong Allelic Association betweentheTorsion Dystonia Gene (DYTI) andLocionChromosome9q34inAshkenazi Jews (1992) (0)
Understanding and Treating Tardive Dyskinesia (1983) (0)
High‐Frequency Palatal Tremor and Stimulus‐Sensitive Leg Myoclonus with Degeneration of Inferior Olivary Nuclei in Celiac Disease (2020) (0)
Parkinson Risk in Ashkenazi Jewish Gaucher Patients and GBA Heterozygotes: Is There a Gene Dose Effect? (P1.015) (2014) (0)
Chapter 18 – Tremors (2011) (0)
Wilson's Disease (1985) (0)
Chapter 19 – Tremors: Diagnosis and Treatment (2007) (0)
biomarkers DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and (2007) (0)
Atypical parkinsonism, parkinsonism-plus syndromes and secondary parkinsonian disorders (2021) (0)
The management of tardive dyskinesia (1986) (0)
Double mutants for Huntington and spinocerebellar ataxia type 2 in a large pedigree segregating both mutations (2000) (0)
Preface (2010) (0)
Letters to the editor (0)
Essential tremor. (1992) (0)
Problems in dys kinesias (1982) (0)
President's Farewell Message (1991) (0)
Surgical treatment of Parkinson disease and other movement disorders (2021) (0)
Principles of molecular genetics/Dystonia (1992) (0)
Reply: Dystonia after severe head injuries (2014) (0)
Neurotransmitter Amino Acids (1977) (0)
Use of a catechol O-methyltransferase inhibitor to enhance central action of L-dopa (1981) (0)
Dystonia clinical research center tissue resource facility: investigations on collected tissue. (1988) (0)
Chapter 22 – The paroxysmal dyskinesias (2011) (0)
Chapter 18 – Stereotypies (2007) (0)
Movement Disorders (1998) (0)
In memoriam: Robert E. Burke, MD, 1949–2018 (2019) (0)
2006 World Parkinson Congress (2006) (0)
Atlas of the Human Skull (1983) (0)
Need for uncombined carbidopa to treat parkinsonism (1978) (0)
Videotapes of motor complications of encephalitis lethargica. (1998) (0)
Chorea, Ballism, and Athetosis (2021) (0)
Author response. (2014) (0)
Introducing a new journal on Parkinson’s disease (2015) (0)
Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
Diagnosis and Medical Management of Dystonia (2009) (0)
Etiology and pathogenesis of Parkinson disease (2021) (0)
FAHN, Stanley: New York/USA (2019) (0)
Editorial (0)
Chapter 13 – Treatment of dystonia (2011) (0)
Sodium-Potassium-activated Adenosine Triphosphatase of l!ZZectrophorus Electric Organ (2003) (0)
Chapter 13 – Dystonia: Phenomenology, Classification, Etiology, Pathology, Biochemistry, and Genetics (2007) (0)
Designing Clinical Trials for Dystonia (2013) (0)
Parkinson's disease slide library (1996) (0)
Transient dystonia asacomplication ofvaricella (1987) (0)
Chapter 14 – Huntington disease (2011) (0)
Chapter 17 – Tics and Tourette Syndrome (2007) (0)
Advances in Neurology, Vol 67 Negative motor phenomena Workshop, April 1994 (1995) (0)
Alzheimer's Disease (1984) (0)
Reply: Diagnosis and management of pergolide‐induced fibrosis (2005) (0)
Antiepileptic Drugs, Ed. 2 (1983) (0)
The Role and Designs of Clinical Trials for Parkinson’s Disease (2004) (0)
Parkinsonism and long‐term levodopa (1980) (0)
Statin Use, Apolipoprotein A1, and Parkinson's Disease (P2.055) (2014) (0)
Masaya Segawa, MD, PhD, 1936-2014. (2015) (0)
Methylprednisolone treatments alter apomorphine-induced circling in the rat model of 6-hydroxydopamine-induced striatal denervation. (1989) (0)
Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease (2021) (0)
Signs and Symptoms in Neurology (1985) (0)
Computed Tomography of the Spine (1983) (0)
Chapter 12 – Stiffness Syndromes (2007) (0)
Tics and Tourette syndrome (2021) (0)
Reply: Oleh Hornykiewicz's contribution to the l‐dopa story (2015) (0)
Search for torsion dystonia gene (1995) (0)
Rare TMEM230 Variants are Potentially Associated With Early Onset Parkinson’s Disease (P3-11.013) (2023) (0)
Alpha Galactosidase A Activity in Parkinson Disease (S45.005) (2018) (0)
SYNTHESIS AND DOPAMINERGIC ACTIVITY OF 3-(3,4-DIHYDROXYPHENYL)-1-N-PROPYLPYRROLIDINE HYDROBROMIDE (1985) (0)
Adaptation of Stability during Perturbed Walking in Parkinson’s Disease (2017) (0)
Oleh Hornykiewicz, a giant in the understanding and treatment of Parkinson disease (2021) (0)
Normal erythrocyte uptake of L‐DOPA in Parkinson's, Huntington's, and related diseases (1983) (0)
Chapter 25 – Wilson Disease (2007) (0)
Preface (2014) (0)
Reply (1997) (0)
Autoimmune movement disorders (2021) (0)
Recent and Relevant (2011) (0)
Stiffness syndromes (2021) (0)
Pathophysiological mechanisms of abverse effects from levodopa therapy (第23回日本神経学会総会(1982)) -- (Generating mechanisms of extrapyramidal symptoms(シンポジウム)) (1982) (0)
List of contributors (2020) (0)
Editorial (0)
Personal reflections about Lewis P. (Bud) Rowland (1925–2017) (2017) (0)
Annual Review of Neuroscience, Vols. 1 and 2 (1979) (0)
Attenuation by electroshock treatment of the haloperidol-induced rise in the binding of 3H-imipramine to rat brain membranes (2004) (0)
Case Study: First Reported Case of Interferon-alpha Induced Postural and Action Tremor (P4.074) (2014) (0)
At jeopardy: the NIH as we know it. (2003) (0)
The Catecholamines in Psychiatric and Neurologic Disorders (1986) (0)
原发性不宁腿综合征的患病率调查——来自上海社区的流行病学研究 (2012) (0)
Ondine's Curse in Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 Caused by MAPT Variants (2021) (0)
Unique Astrocyte Pathology in a Case of Rapid Onset Dystonia-Parkinsonism (DYT12) with Novel Mutation in ATP1A3 (P2.137) (2015) (0)
Immunocytochemical staining of Lewy bodies with antibodies to cytoskeleton proteins. (1987) (0)
Non-Parkinsonian Movement Disorders (2015) (0)
Chapter 22 – Ataxia: Pathophysiology and Clinical Syndromes (2007) (0)
Progress in Psychiatry (1900) (0)
What is it? Commentary (1990) (0)
Clinical Pharmacology of Serotonin. Satellite Symposium on the Clinical Pharmacology of Serotonin, Helsinki, July 1975 (1977) (0)
The Effect of Parkin Mutation Status on Cognitive Functioning in EOPD Patients with Long Disease Duration: The CORE-PD Study (PD7.008) (2012) (0)
Textbook of C1inical Neuropharmacology (1983) (0)
What is it? Case 1, 1992: Progressive gait deterioration, peripheral neuropathy, optic atrophy, bradykinesia, and dystonia in a young girl (1992) (0)
Erratum: Emerging topics in FXTAS (2015) (0)
Parkinson disease penetrance in patients with Gaucher disease and in glucocerebrosidase mutation carriers (2014) (0)
Frontiers of science and clinical advances in quality of life in Parkinson's disease. Preface. (2010) (0)
Editorial (2000) (0)
New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
Progress in psychiatry. (1994) (0)
MATTERS ARISING (1985) (0)
The Epidemiology of Dementia (1983) (0)
Wilson disease (2021) (0)
Video Review of Baseline Performance on Global Ratings in a Double‐Blind Placebo Surgery Trial (2018) (0)
Delayed‐onset dystonia (1991) (0)
At jeopardy: the NIH as we know it. (2003) (0)
Editorial (0)
Introduction (0)
Parkinson's disease (Advances in neurology, Vol. 45), by M. D. Yahr and K. J. Bergmann, Raven Press, New York, 1987, 640 pp, $98.50 (1988) (0)
Chapter 23 – Restless legs and peripheral movement disorders (2011) (0)
Letters to the Editor (1997) (0)
Oliver Sacks, MD, 1933-2015. (2016) (0)
Paroxysmal dyskinesias (2021) (0)
Pathology of Perinatal Brain Injury (1983) (0)
Mechanisms of Cutaneous Sensation (1984) (0)
Motor control (2019) (0)
Principles of Neuroanatomy (1983) (0)
Sequencing the entire exome of REM sleep behavior and progression to neurodegenerative diseases (2020) (0)
Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD (2011) (0)
CURRENT TRENDS IN THE TREATMENT OF BASAL GANGLIA DISEASES (1990) (0)
Report to the members of the Movement Disorder Society (1989) (0)
Erratum: Huntington's disease-like 2 (HDL2) in North America and Japan (Annals of Neurology (November 2004) 56 (670-674)) (2004) (0)
Letters to the Editor (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stanley Fahn?

Stanley Fahn is affiliated with the following schools:

Columbia University